| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD23 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C2115H3252N556O673S16 |
| Molar mass | 47749.46 g·mol−1 |
 N Y (what is this?) (verify) | |
Lumiliximab is an IgG1kmonoclonal antibody that targetsCD23. It acts as animmunomodulator[1] and was awardedorphan drug status andfast track designation by the FDA.[2]
It was investigated in Phase II/IIIclinical trials for the treatment ofchronic lymphocytic leukemia.[3][4] It has also been studied for use inallergic asthma. The drug is achimeric antibody fromMacaca irus andHomo sapiens.[1]
Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired byBiogen.Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.[2] Results published from the CLL clinical trial failed to meet primary endpoints.[5]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
